CPIX supply chain intelligence for Cumberland Pharmaceuticals Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
Cumberland Pharmaceuticals Inc. (CPIX) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| APOTEX-INC | APOTEX-INC | 92% | Through the Transaction Apotex will create a U.S. branded pharmaceutical platform to build upon, by delivering specialty medicines that improve the quality of patient care. |
| 1600-WEST-END-AVENUE-PARTNERS-LLC | 1600-WEST-END-AVENUE-PARTNERS-LLC | 90% | On November 15, 2021, Cumberland entered into a lease (the "Broadwest Lease"), pursuant to which the Company leases approximately 16,903 rentable square feet of space (the "Leased Premise") at the Br… |
| KYOWA-KIRIN-INC | KYOWA-KIRIN-INC | 90% | On January 3, 2022, Cumberland acquired the U.S. rights to the FDA-approved oncology-supportive care medicine Sancuso from Kyowa Kirin, Inc. ("Kyowa Kirin"), the U.S. affiliate of Japan-based Kyowa K… |
| NORDIC-B-V | NORDIC-B-V | 90% | Effective June 30, 2023, the Company returned all rights of RediTrex back to Nordic B.V., and will receive a long-term royalty on any sales of the product in the future. |
| THERAVANCE | THERAVANCE | 80% | The contingent consideration earned and accrued in operating expenses is paid to Theravance quarterly. |
| HRTX | Heron Therapeutics, Inc. | 72% | Reciprocal relationship from HRTX graph: omer-based composition. Furthermore, our Biochronomer Technology is designed to permit more than one pharmacological agent to be incorporated, such that multi… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| CHINA-DISTRIBUTION-PARTNER | CHINA-DISTRIBUTION-PARTNER | 90% | In early 2025, Cumberland received a $ 3.0 million milestone payment from our distribution partner in China associated with the approval of Vibativ for that market. |
| HRTX | Heron Therapeutics, Inc. | 72% | Reciprocal relationship from HRTX graph: Reciprocal relationship from CPIX graph: Reciprocal relationship from HRTX graph: omer-based composition. Furthermore, our Biochronomer Technology is designed… |
| CUMBERLAND-EMERGING-TECHNOLOGIES-INC | CUMBERLAND-EMERGING-TECHNOLOGIES-INC | 62% | ty rate was subsequently reduced to 5 % in early 2025. The future royalty payments were required to be recognized at their acquisition-date fair value as a contingent consideration liability, as part… |
| JAPAN-BASED-KYOWA-KIRIN-CO-LTD | JAPAN-BASED-KYOWA-KIRIN-CO-LTD | 62% | ancuso from Kyowa Kirin, Inc. ("Kyowa Kirin"), the U.S. affiliate of Japan-based Kyowa Kirin Co., Ltd. Sancuso is the first and only FDA-approved prescription patch for the prevention of nausea and v… |
| KYOWA-KIRIN-INC | KYOWA-KIRIN-INC | 62% | ancuso from Kyowa Kirin, Inc. ("Kyowa Kirin"), the U.S. affiliate of Japan-based Kyowa Kirin Co., Ltd. Sancuso is the first and only FDA-approved prescription patch for the prevention of nausea and v… |
| NASHVILLE-LLC | NASHVILLE-LLC | 62% | h the acquisition of those brands and are also included in the raw materials inventory. As these APIs are consumed in the manufacture of our products, the value of the API involved is transferred fro… |
| NORDIC-GROUP | NORDIC-GROUP | 62% | ty rate was subsequently reduced to 5 % in early 2025. The future royalty payments were required to be recognized at their acquisition-date fair value as a contingent consideration liability, as part… |
| WEST-END-AVENUE-PARTNERS-LLC | WEST-END-AVENUE-PARTNERS-LLC | 62% | h the acquisition of those brands and are also included in the raw materials inventory. As these APIs are consumed in the manufacture of our products, the value of the API involved is transferred fro… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| CPIX-DEBT | Debt stack $10.1M | 90% | Market cache reports total debt of $10.1M. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| CPIX-OWNER-VANGUARD-GROUP-INC | Vanguard Group Inc | 95% | 13F/ownership overlay lists Vanguard Group Inc; shares held 411,786; ownership 2.75%; value $1.3M; as of 2025-12-31. |
| CPIX-OWNER-BRIDGEWAY-CAPITAL-MANAGEMENT-LLC | Bridgeway Capital Management, LLC | 95% | 13F/ownership overlay lists Bridgeway Capital Management, LLC; shares held 163,468; ownership 1.09%; value $498,577; as of 2025-12-31. |
| CPIX-OWNER-J-GOLDMAN-CO-L-P | J. Goldman & Co., L.P. | 95% | 13F/ownership overlay lists J. Goldman & Co., L.P.; shares held 94,541; ownership 0.63%; value $288,350; as of 2025-12-31. |
| CPIX-OWNER-IKARIAN-CAPITAL-LLC | Ikarian Capital, LLC | 95% | 13F/ownership overlay lists Ikarian Capital, LLC; shares held 555,932; ownership 3.72%; value $1.7M; as of 2025-12-31. |
| CPIX-OWNER-PERCEPTIVE-ADVISORS-LLC | Perceptive Advisors Llc | 95% | 13F/ownership overlay lists Perceptive Advisors Llc; shares held 341,087; ownership 2.28%; value $1.0M; as of 2025-12-31. |
| CPIX-OWNER-DIMENSIONAL-FUND-ADVISORS-LP | Dimensional Fund Advisors LP | 95% | 13F/ownership overlay lists Dimensional Fund Advisors LP; shares held 272,278; ownership 1.82%; value $830,447; as of 2025-12-31. |
| CPIX-OWNER-GEODE-CAPITAL-MANAGEMENT-LLC | Geode Capital Management, LLC | 95% | 13F/ownership overlay lists Geode Capital Management, LLC; shares held 107,274; ownership 0.72%; value $327,185; as of 2025-12-31. |
| CPIX-OWNER-BANK-OF-NEW-YORK-MELLON-CORPORATION | Bank Of New York Mellon Corporation | 95% | 13F/ownership overlay lists Bank Of New York Mellon Corporation; shares held 72,513; ownership 0.48%; value $221,164; as of 2025-12-31. |
| CPIX-OWNER-RENAISSANCE-TECHNOLOGIES-LLC | Renaissance Technologies, LLC | 95% | 13F/ownership overlay lists Renaissance Technologies, LLC; shares held 472,163; ownership 3.16%; value $1.4M; as of 2025-12-31. |
| CPIX-OWNER-BOOTHBAY-FUND-MANAGEMENT-LLC | Boothbay Fund Management, LLC | 95% | 13F/ownership overlay lists Boothbay Fund Management, LLC; shares held 128,507; ownership 0.86%; value $391,946; as of 2025-12-31. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| HRTX | Heron Therapeutics, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| HTGC | Hercules Capital, Inc. | 50.00 | 2 | |
| ORANY | ORANGE | 50.00 | 2 | |
| BAX | Baxter International Inc. | 50.00 | 2 | |
| MRK | Merck & Co., Inc. | 50.00 | 2 | |
| PCRX | Pacira BioSciences, Inc. | 50.00 | 2 | |
| TKPHF | Takeda Pharmaceutical Company Limited | 50.00 | 2 |